Clinical Neurology NewsNeuronal protein could be multiple sclerosis blood biomarkerOctober 1, 2016Multiple Sclerosis
Neurology ReviewsRetinal Measurements Predict 10-Year Disability in MSSeptember 30, 2016Multiple Sclerosis
Neurology ReviewsCan Neurologists Predict Long-Term Disability Trajectories in Primary Progressive MS?September 30, 2016Multiple Sclerosis
Neurology ReviewsClinical Considerations of New and Pending MS TreatmentsSeptember 30, 2016Multiple Sclerosis
Clinical Neurology NewsMobility benefits of MS drug dalfampridine confirmed by patient-reported outcomesSeptember 29, 2016Multiple Sclerosis
Clinical Neurology NewsAlemtuzumab, natalizumab found equally effective for relapsing-remitting MSSeptember 22, 2016Multiple Sclerosis
Neurology ReviewsOcrelizumab Increases Likelihood of No Evidence of Disease Progression September 20, 2016Multiple Sclerosis
Neurology ReviewsArbaclofen Extended-Release Tablets Are Effective for MS SpasticitySeptember 20, 2016Multiple Sclerosis
Clinical Neurology NewsSiponimod curbs disability in secondary progressive multiple sclerosisSeptember 20, 2016Multiple Sclerosis
Clinical Neurology NewsEuropean guidelines cover entire spectrum of MS treatmentSeptember 19, 2016Multiple Sclerosis
Neurology ReviewsDurable Efficacy of Alemtuzumab: Five-Year Follow-Up of the CARE-MS StudiesSeptember 16, 2016Multiple Sclerosis
Neurology ReviewsDoes the EDSS Capture Cognitive Difficulties in Patients With MS? September 16, 2016Multiple Sclerosis
Neurology ReviewsCan Neurologists Predict Long-Term Disability Trajectories in Primary Progressive MS?September 16, 2016Multiple Sclerosis
